Form 4: ImmunityBio Director Cheryl Cohen Receives Stock Options
Director Equity Grant Disclosure
ImmunityBio director Cheryl Cohen was granted 65,600 stock options as part of the company's 2025 Equity Incentive Plan.
Summary
- Director Cheryl Cohen received a grant of 65,600 stock options on June 9, 2026.
- The options have an exercise price of $7.25 per share.
- The options are set to vest in full on the earlier of June 9, 2027, or the day before the next annual stockholders' meeting, provided the director remains a service provider.
- The options have an expiration date of June 9, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative disclosure regarding director compensation, which carries a neutral sentiment.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- Dilutive impact of new option grants on existing shareholders.
Risks
- Vesting is contingent upon the director's continued service to the company.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of an equity grant to a director.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to incentivize long-term oversight and strategic alignment, particularly for companies in the clinical development stage.
Comparison to Industry Standards
- The use of a one-year cliff vesting schedule is consistent with standard corporate governance practices for non-employee director compensation in the U.S. biotech industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Filing of a new Power of Attorney authorizing specific individuals to sign SEC filings on behalf of the director. | 2025-10-30 | Standard administrative update to facilitate regulatory compliance. |
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual exercise of these options.
Next Steps
- Vesting of options on June 9, 2027, or the date preceding the next annual meeting.
Key Dates
| Date | Description |
|---|---|
| 2025-10-30 | Date of Power of Attorney execution. |
| 2026-06-09 | Date of grant and earliest transaction. |
| 2027-06-09 | Vesting date for the stock options. |
| 2036-06-09 | Expiration date for the stock options. |
Keywords
ImmunityBio, IBRX, Director Compensation, Stock Options, Equity Incentive Plan, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.